scispace - formally typeset
A

Angel Chinea

Publications -  8
Citations -  490

Angel Chinea is an academic researcher. The author has contributed to research in topics: Medicine & Multiple sclerosis. The author has an hindex of 1, co-authored 1 publications receiving 369 citations.

Papers
More filters
Journal ArticleDOI

A comprehensive review of amyotrophic lateral sclerosis.

TL;DR: This study provides a comprehensive review of ALS covering all aspects of the disease including epidemiology, comorbidities, environmental risk factor, molecular mechanism, genetic factors, symptoms, diagnostic, treatment, and even the available supplement and management.
Journal ArticleDOI

Ancestral risk modification for multiple sclerosis susceptibility detected across the Major Histocompatibility Complex in a multi-ethnic population

TL;DR: In this paper , the authors identify MHC-specific MS susceptibility variants and assess the effect of ancestral risk modification within 2652 Latinx and Hispanic individuals as well as 2435 Black and African American individuals.
Proceedings ArticleDOI

An Interim Analysis of Efficacy and Safety Data in Black and Hispanic Patients With Multiple Sclerosis Receiving Ocrelizumab Treatment in the CHIMES Trial (S31.006)

TL;DR: The CHIMES trial as discussed by the authors was designed to evaluate disease activity and OCR response in Black and Hispanic patients with relapsing multiple sclerosis (pwRMS) who self-identified as Black or Hispanic, were aged 18-65 years and had Expanded Disability Status Scale (EDSS) scores of 0-5.
Journal ArticleDOI

Epidemiologic trends of multiple sclerosis in Puerto Rico (2013-2020).

TL;DR: A total of 568 new MS cases were diagnosed in Puerto Rico between 2017 and 2020 and the 2020 MS cumulative prevalence for Puerto Rico was 95.3/100,000 (95% CI: 91.6, 99.1), higher than previously reported as discussed by the authors .
Journal ArticleDOI

Real-World Safety and Effectiveness After 5 Years of Dimethyl Fumarate Treatment in Black and Hispanic Patients with Multiple Sclerosis in ESTEEM.

TL;DR: In this article , the authors evaluated the real-world safety and effectiveness of dimethyl fumarate (DMF) treatment over 5 years in four patient cohorts: Black, non-Black, Hispanic, and non-Hispanic people with relapsing-remitting MS.